Recent filings with the Securities and Exchange Commission (SEC) reveal a notable transaction involving J. Robert Kerrey, a director at Tenet Healthcare Corp (NYSE:THC). On May 28, 2026, Mr. Kerrey executed the sale of common stock valued at $983,920. The specifics of this divestiture included selling 5,638 shares, with the transaction prices ranging between $173.12 and $177.52 per share.
The report detailing these sales was officially filed on May 29, 2026. Following the sale, Mr. Kerrey's direct holdings of Tenet Healthcare common stock were reduced to 16,804 shares. This director activity is noted against a backdrop of various market data points for the $15 billion healthcare provider. Currently, THC trades at a Price-to-Earnings (P/E) ratio of 9.23, and analysis from InvestingPro suggests that the stock may remain undervalued when measured against its Fair Value, positioning it among stocks identified as highly undervalued.
Despite this reduction in his personal stake, the data presents mixed signals regarding internal confidence. While Mr. Kerrey sold shares, InvestingPro data also indicates a pattern of aggressive share buybacks by management. Furthermore, the company maintains a robust financial standing, evidenced by its